|
1
|
Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T
and Si J: Down-regulation of miR-141 in gastric cancer and its
involvement in cell growth. J Gastroenterol. 44:556–561. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus
surgery alone for resectable gastroesophageal cancer. N Engl J Med.
355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fang L, Li H, Wang L, Hu J, Jin T, Wang J
and Yang BB: MicroRNA-17-5p promotes chemotherapeutic drug
resistance and tumour metastasis of colorectal cancer by repressing
PTEN expression. Oncotarget. 5:2974–2987. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rivera F, Vega-Villegas ME and Lόpez-Brea
MF: Chemotherapy of advanced gastric cancer. Cancer Treat Rev.
33:315–324. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang
B, Shu Y and Liu P: MiR-497 modulates multidrug resistance of human
cancer cell lines by targeting BCL2. Med Oncol. 29:384–391. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNA in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kovalchuk O, Filkowski J, Meservy J,
Ilnytskyy Y, Tryndyak VP, Chekhun VF and Pogribny IP: Involvement
of microRNA-451 in resistance of the MCF-7 breast cancer cells to
chemotherapeutic drug doxorubicin. Mol Cancer Ther. 7:2152–2159.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu H, Li S, Cui X, Lv X, Jiao Y, Yu F, Yao
H, Song E, Chen Y, Wang M and Lin L: The overexpression of
hypomethylated miR-663 induces chemotherapy resistance in human
breast cancer cells by targeting heparin sulfate proteoglycan 2
(HSPG2). J Biol Chem. 288:10973–10985. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luo HC: MiRNAs expression profiling of
gastric carcinoma and function of significantly down-regulated
miR-9 and miR-433. Chongqing Chongqing Med Univ. 1–85. 2010.
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fojo T: Multiple paths to a drug
resistance phenotype: Mutations, translocations, deletions and
amplification of coding genes or promoter regions, epigenetic
changes and microRNA. Drug Resist Updat. 10:59–67. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun
S, Hong L, Liu J and Fan D: MiR-15b and miR-16 modulate multidrug
resistance by targeting BCL2 in human gastric cancer cells. Int J
Cancer. 123:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kastl L, Brown I and Schofield AC:
MiRNAs-34a is associated with docetaxel resistance in human breast
cancer cells. Breast Cancer Res Treat. 131:445–454. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ueda T, Volinia S, Okumura H, Shimizu M,
Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al:
Relation between microRNA expression and progression and prognosis
of gastric cancer: A microRNA expression analysis. Lancet Oncol.
11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Szakács G, Paterson JK, Ludwig JA,
Booth-genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He L, Thomson JM, Hemann MT,
Hernando-monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ and Hammond SM: A microRNA polycistron as a potential
human oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Motoyama K, Inoue H, Takatsuno Y, Tanaka
F, Mimori K, Uetake H, Sugihara K and Mori M: Over- and
under-expressed microRNAs in human colorectal cancer. Int J Oncol.
34:1069–1075. 2009.PubMed/NCBI
|
|
18
|
Schetter AJ, Leung SY, Sohn JJ, Zanetti
KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et
al: MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:pp. 2257–2261.
2006; View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li X, Zhang Y, Zhang Y, Ding J, Wu K and
Fan D: Survival prediction of gastric cancer by a seven-microRNA
signature. Gut. 59:579–585. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dews M, Fox JL, Hultine S, Sundaram P,
Wang W, Liu YY, Furth E, Enders GH, El-Deiry W, Schelter JM, et al:
The myc-miR-17~92 axis blunts TGF{beta} signaling and production of
multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res.
70:8233–8246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu Q, Luo G, Yang Z, Zhu F, An Y, Shi Y
and Fan D: miR-17-5p promotes proliferation by targeting SOCS6 in
gastric cancer cells. FEBS Lett. 588:2055–2062. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fontana L, Fiori ME, Albini S, Cifaldi L,
Giovinazzi S, Forloni M, Boldrini R, Donfrancesco A, Federici V,
Giacomini P, et al: Antagomir-17-5p abolishes the growth of
therapy-resistant neuroblastoma through p21 and BIM. PLoS One.
3:e22362008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan HL, Xue G, Mei Q, Wang YZ, Ding FX,
Liu MF, Lu MH, Tang Y, Yu HY and Sun SH: Repression of the
miR-17-92 cluster by p53 has an important function in
hypoxia-induced apoptosis. EMBO J. 28:2719–2732. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen Y, Lu L, Xu J, Meng W, Qing Y, Liu Y,
Zhang B and Hu H: Bortezomib induces apoptosis of endometrial
cancer cells through microRNA-17-5p by targeting p21. Cell Biol
Int. 37:1114–1121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huether A, Höpfner M, Baradari V, Schuppan
D and Scherübl H: EGFR blockade by cetuximab alone or as
combination therapy for growth control of hepatocellular cancer.
Biochem Pharmacol. 70:1568–1578. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fan M, Sethuraman A, Brown M, Sun W and
Pfeffer LM: Systematic analysis of metastasis-associated genes
identifies miR-17-5p as a metastatic suppressor of basal-like
breast cancer. Breast Cancer Res Treat. 146:487–502. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chatterjee A, Chattopadhyay D and
Chakrabarti G: miR-17-5p downregulation contributes to paclitaxel
resistance of lung cancer cells through altering beclin1
expression. PLoS One. 9:e957162014. View Article : Google Scholar : PubMed/NCBI
|
